These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 26047735)

  • 21. Human single-chain Fv intrabodies counteract in situ huntingtin aggregation in cellular models of Huntington's disease.
    Lecerf JM; Shirley TL; Zhu Q; Kazantsev A; Amersdorfer P; Housman DE; Messer A; Huston JS
    Proc Natl Acad Sci U S A; 2001 Apr; 98(8):4764-9. PubMed ID: 11296304
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Secondary structures of native and pathogenic huntingtin N-terminal fragments.
    Długosz M; Trylska J
    J Phys Chem B; 2011 Oct; 115(40):11597-608. PubMed ID: 21910495
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Polyglutamine tracts regulate beclin 1-dependent autophagy.
    Ashkenazi A; Bento CF; Ricketts T; Vicinanza M; Siddiqi F; Pavel M; Squitieri F; Hardenberg MC; Imarisio S; Menzies FM; Rubinsztein DC
    Nature; 2017 May; 545(7652):108-111. PubMed ID: 28445460
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Structure and Dynamics of the Huntingtin Exon-1 N-Terminus: A Solution NMR Perspective.
    Baias M; Smith PE; Shen K; Joachimiak LA; Żerko S; Koźmiński W; Frydman J; Frydman L
    J Am Chem Soc; 2017 Jan; 139(3):1168-1176. PubMed ID: 28085263
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Secondary structure of Huntingtin amino-terminal region.
    Kim MW; Chelliah Y; Kim SW; Otwinowski Z; Bezprozvanny I
    Structure; 2009 Sep; 17(9):1205-12. PubMed ID: 19748341
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Beta conformation of polyglutamine track revealed by a crystal structure of Huntingtin N-terminal region with insertion of three histidine residues.
    Kim M
    Prion; 2013; 7(3):221-8. PubMed ID: 23370273
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Identifying polyglutamine protein species in situ that best predict neurodegeneration.
    Miller J; Arrasate M; Brooks E; Libeu CP; Legleiter J; Hatters D; Curtis J; Cheung K; Krishnan P; Mitra S; Widjaja K; Shaby BA; Lotz GP; Newhouse Y; Mitchell EJ; Osmand A; Gray M; Thulasiramin V; Saudou F; Segal M; Yang XW; Masliah E; Thompson LM; Muchowski PJ; Weisgraber KH; Finkbeiner S
    Nat Chem Biol; 2011 Oct; 7(12):925-34. PubMed ID: 22037470
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Aggregation landscapes of Huntingtin exon 1 protein fragments and the critical repeat length for the onset of Huntington's disease.
    Chen M; Wolynes PG
    Proc Natl Acad Sci U S A; 2017 Apr; 114(17):4406-4411. PubMed ID: 28400517
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Spontaneous self-assembly of pathogenic huntingtin exon 1 protein into amyloid structures.
    Trepte P; Strempel N; Wanker EE
    Essays Biochem; 2014; 56():167-80. PubMed ID: 25131594
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antibodies against huntingtin: production and screening of monoclonals and single-chain recombinant forms.
    Khoshnan A; Ou S; Ko J; Patterson PH
    Methods Mol Biol; 2004; 277():87-102. PubMed ID: 15201451
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Polyglutamine disruption of the huntingtin exon 1 N terminus triggers a complex aggregation mechanism.
    Thakur AK; Jayaraman M; Mishra R; Thakur M; Chellgren VM; Byeon IJ; Anjum DH; Kodali R; Creamer TP; Conway JF; Gronenborn AM; Wetzel R
    Nat Struct Mol Biol; 2009 Apr; 16(4):380-9. PubMed ID: 19270701
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Targeting aggregation in the development of therapeutics for the treatment of Huntington's disease and other polyglutamine repeat diseases.
    Steffan JS; Thompson LM
    Expert Opin Ther Targets; 2003 Apr; 7(2):201-13. PubMed ID: 12667098
    [TBL] [Abstract][Full Text] [Related]  

  • 33. β-hairpin-mediated nucleation of polyglutamine amyloid formation.
    Kar K; Hoop CL; Drombosky KW; Baker MA; Kodali R; Arduini I; van der Wel PC; Horne WS; Wetzel R
    J Mol Biol; 2013 Apr; 425(7):1183-97. PubMed ID: 23353826
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Control of the structural landscape and neuronal proteotoxicity of mutant Huntingtin by domains flanking the polyQ tract.
    Shen K; Calamini B; Fauerbach JA; Ma B; Shahmoradian SH; Serrano Lachapel IL; Chiu W; Lo DC; Frydman J
    Elife; 2016 Oct; 5():. PubMed ID: 27751235
    [TBL] [Abstract][Full Text] [Related]  

  • 35. N-Terminal Fragments of Huntingtin Longer than Residue 170 form Visible Aggregates Independently to Polyglutamine Expansion.
    Chen MZ; Mok SA; Ormsby AR; Muchowski PJ; Hatters DM
    J Huntingtons Dis; 2017; 6(1):79-91. PubMed ID: 28339398
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mutant huntingtin forms in vivo complexes with distinct context-dependent conformations of the polyglutamine segment.
    Persichetti F; Trettel F; Huang CC; Fraefel C; Timmers HT; Gusella JF; MacDonald ME
    Neurobiol Dis; 1999 Oct; 6(5):364-75. PubMed ID: 10527804
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A toxic mutant huntingtin species is resistant to selective autophagy.
    Fu Y; Wu P; Pan Y; Sun X; Yang H; Difiglia M; Lu B
    Nat Chem Biol; 2017 Nov; 13(11):1152-1154. PubMed ID: 28869595
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Intrabodies binding the proline-rich domains of mutant huntingtin increase its turnover and reduce neurotoxicity.
    Southwell AL; Khoshnan A; Dunn DE; Bugg CW; Lo DC; Patterson PH
    J Neurosci; 2008 Sep; 28(36):9013-20. PubMed ID: 18768695
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparative study of naturally occurring huntingtin fragments in Drosophila points to exon 1 as the most pathogenic species in Huntington's disease.
    Barbaro BA; Lukacsovich T; Agrawal N; Burke J; Bornemann DJ; Purcell JM; Worthge SA; Caricasole A; Weiss A; Song W; Morozova OA; Colby DW; Marsh JL
    Hum Mol Genet; 2015 Feb; 24(4):913-25. PubMed ID: 25305076
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cellular toxicity of polyglutamine expansion proteins: mechanism of transcription factor deactivation.
    Schaffar G; Breuer P; Boteva R; Behrends C; Tzvetkov N; Strippel N; Sakahira H; Siegers K; Hayer-Hartl M; Hartl FU
    Mol Cell; 2004 Jul; 15(1):95-105. PubMed ID: 15225551
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.